SynthesisScientific reports2024
Quality of life and utility of patients with peripheral artery disease (PAD): a systematic review and meta-analysis.
Synthesis in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Estimating the Clinical, Quality-of-Life and Economic Impact of Optimized Management of Type 2 Diabetes Patients in Spain.Journal of clinical medicine · 2026Article
- The Effect of Vitamin D Supplementation on Ankle-brachial Index in Patients with Type 2 Diabetes: A Randomized Clinical Trial.Iranian journal of nursing and midwifery researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Peripheral artery disease (PAD) patients experience low utility, especially those having undergone amputation. Utility is one of the quality weights of health status, converted from quality of life (QOL). This study aimed to systematically review published literature and analyze a pooled estimate of utility in PAD patients. The following databases were queried for articles published from inception up to August 30, 2022: PubMed, ScienceDirect, Scopus, ThaiJo, and the Thai thesis database. Four quality assessment tools were used, tailored to each study's design. A pooled utility was estimated by the random effect and reported using Rutherford and Fontaine classification systems due to their common use in practice. The protocol was registered with the International Prospective Registration of Systematic Reviews (CRD42023392775). Fourteen high-quality studies were included, pooling utility from 3,664 PAD patients. The pooled utility by the Rutherford categories was 0.67, with scores for categories 0, 1-3, 4, and 5 being 0.88, 0.65, 0.68, and 0.58, respectively. The pooled utility by the Fontaine stage was 0.68, with stages 1, 2, 3, and 4 scoring 0.88, 0.65, 0.67, and 0.58, respectively. PAD utility is comparable to that of other chronic diseases. The pooled utility could be a valuable parameter for cost-utility analysis in PAD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.